A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

Inclusion Criteria: * Hemodialysis treatment for ≥ 6 months * Phosphate binder treatment for ≥ to 1 month * Maintenance iron therapy with no more than 125mg IV iron weekly≥ to 1 month * Serum phosphorus levels between 2.5 and 8 at screening * Serum phosphorus ≥ to 6.0 mg/dL after a 2 week washout period. * Serum ferritin ≥ 200 and \< 600ng/ml after a 2 week washout period * Serum calcium levels within normal range * Predicted survival greater than 6 months Exclusion Criteria: * Intact PTH\< 70 pg/ml or \> 1,000 pg/ml * Oral iron use * Vitamin C supplement use * Parathyroidectomy * Active malignancy * Hemodialysis via an intravenous catheter or arteriovenous (AV) graft * Received \> 250mg of IV iron over the two weeks prior to screening * Whole blood transfusion within 3 months prior to screening * Active bleeding other than from the dialysis access * Hospitalization within one month prior to screening * current infection * Ongoing or uncontrolled inflammatory disorder * Liver cirrhosis * Likelihood of imminent renal transplantation